Henoch-Schönlein Purpura
Henoch-Schönlein purpura (HSP) is a systemic vasculitis primarily affecting children but can also occur in adults. It is characterized by the deposition of immune complexes, primarily composed of IgA, in small blood vessels throughout the body. Our company is a leading CRO in the field of autoimmune disease research and development, dedicated to providing therapy development services for Henoch-Schönlein purpura.
Introduction to Henoch-Schönlein Purpura
Henoch-Schönlein purpura, also referred to as immunoglobulin A vasculitis (IgAV), is an immune-mediated disease that manifests as a combination of skin rash (purpura), joint pain (arthralgia), abdominal pain, and kidney involvement. The pathogenesis of HSP involves the activation of the immune system, leading to the deposition of immune complexes in blood vessel walls. These immune complexes trigger an inflammatory response, resulting in vasculitis and subsequent tissue damage. The deposition of IgA immune complexes is a hallmark of HSP, although the exact mechanisms behind their formation and deposition remain under investigation.
Fig.1 Age and sex distribution at the onset of the Henoch-Schönlein purpura. (Kim W. K., et al., 2021)
Drug Discovery and Development for Henoch-Schönlein Purpura
Currently, the optimal therapeutic approach for HSP remains a topic of debate and research. The primary focus of therapy is on symptom management, particularly for abdominal and joint pains, which may require the use of analgesics. In cases of severe gastrointestinal or renal involvement, corticosteroids may be considered to alleviate symptoms and reduce the risk of complications. In addition to corticosteroids, other immunosuppressive therapies such as cyclophosphamide and dipyridamole, as well as intravenous immunoglobulin (IVIG), have shown promise in specific cases of severe HSP.
Our dedicated team of scientists and researchers is actively engaged in the development of novel therapies for HSP. Leveraging our expertise in immunology, pharmacology, and drug discovery, we are committed to identifying and targeting key pathways involved in HSP pathogenesis. You can click on the links below to find the right therapeutic development solution for you.
Our Services
As a leader in autoimmune diseases research and development, our company is at the forefront of advancing the understanding and therapy development of HSP. We offer a comprehensive range of diagnostics and therapy development services tailored specifically to Henoch-Schönlein purpura (HSP).
HSP Rat Models
Development of a rat model for HSP involves inducing a type III hypersensitivity reaction through the administration of ovalbumin (OVA). In our research, we established HSP rat models by treating the animals with a compound solution derived from ginger, long pepper, and pepper decoction.
HSP Rabbit Models
Following the administration of the compound solution derived from ginger, long pepper, and pepper decoction, the HSP rabbit models receive ovalbumin (OVA) physiological saline liquor either by ear vein injection or intradermal injection.
By utilizing primary human endothelial cells and neutrophils, we recreate the IgA1-immune complex deposition and subsequent neutrophil activation, enabling detailed analysis of the cellular and molecular events involved in HSP development.
HSP is characterized by vascular inflammation and glomerular dysfunction, often leading to glomerulonephritis. Our organoid models provide a unique opportunity to study these pathological processes in vitro.
Our company offers comprehensive preclinical research services for HSP, including efficacy testing, pharmacokinetic assessments, and safety evaluations. Along with the aforementioned services and models, we also offer tailored services and the development of disease models to cater to your specific requirements. If you have an interest in our services, please feel free to contact us without any hesitation.
References
- Kim W. K., et al. "Risk factors for renal involvement in Henoch-Schönlein purpura." Jornal de pediatria 97 (2021): 646-650.
- Cao T., et al. "Risk factors associated with recurrence of Henoch-Schonlein purpura: a retrospective study." Frontiers in Pediatrics 11 (2023): 1164099.